skip to Main Content

06-08 February

Prague, Czech Republic

Scientific Programme - Topics to be covered
  • Preclinical research on the mechanisms of malignant transformation of hepatic cells and of cell-to-cell interactions
  • Basic and translational research on the biology, genetics, and immunology of HCC and CCA
  • New developments in HCC and CCA management, including new targeted agents and recent data and implications for immunotherapy of HCC and CCA
  • Personalized medicine
  • The new challenge of microbiota and liver cancer
  • Novel biomarker concepts in HCC and CCA
  • Discussions on clinical trials between academia, pharma and regulatory agencies

Find out more about EASL. Also discover EASL’s LinkedIn page for the latest news.